Genetic testing specialist 23andMe has launched a strategic review that could result in a sale of the company, after months of speculation about its future. The company's board has formed a ...

SUNNYVALE, Calif. and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, today announced the launch of Discover23®, a new research ...

23andMe is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing business. A special committee of its directors’ board is considering ...

23andMe CEO Anne Wojcicki sounded optimistic about the company's future during an earnings call in February last year. She said the biotech company, which offers direct-to-consumer genetic testing ...

23andMe Holding Co. has launched a new polygenic risk score (PRS) report for osteoporosis, available to 23andMe+ Premium members. This report assesses an individual's genetic likelihood of ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses. The company that made its name by providing saliva ...

Genetic testing firm 23andMe (NASDAQ:ME) said it formed a special board committee to review strategic alternatives. The special committee will look at options including a sale, business ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year ...

SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human ...